{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:54:04Z","timestamp":1778673244505,"version":"3.51.4"},"reference-count":123,"publisher":"Elsevier","isbn-type":[{"value":"9780128040133","type":"print"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/bs.irn.2016.02.005","type":"book-chapter","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T15:19:10Z","timestamp":1457623150000},"page":"87-120","source":"Crossref","is-referenced-by-count":16,"title":["Screening Medications for the Treatment of Cannabis Use Disorder"],"prefix":"10.1016","author":[{"given":"L.V.","family":"Panlilio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Justinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0010","doi-asserted-by":"crossref","first-page":"e44864","DOI":"10.1371\/journal.pone.0044864","article-title":"Quantifying the clinical significance of cannabis withdrawal","volume":"7","author":"Allsop","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cpt.109","article-title":"Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal","volume":"97","author":"Allsop","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2016.02.005_bb0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fphar.2014.00044","article-title":"Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: Evaluation of possible serotonergic and dopaminergic underlying mechanisms","volume":"5","author":"Amchova","year":"2014","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0025","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/1516-4446-2013-1244","article-title":"Systematic review of N-acetylcysteine in the treatment of addictions","volume":"36","author":"Asevedo","year":"2014","journal-title":"Revista Brasileira de Psiquiatria"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40429-014-0011-1","article-title":"Novel pharmacologic approaches to treating Cannabis use disorder","volume":"1","author":"Balter","year":"2014","journal-title":"Current Addiction Reports"},{"key":"10.1016\/bs.irn.2016.02.005_bb0040","first-page":"1","article-title":"Comparing and evaluating substance use treatment utilization estimates from the national survey on drug use and health and other data sources","author":"Batts","year":"2014","journal-title":"CBHSQ Data Review"},{"issue":"5","key":"10.1016\/bs.irn.2016.02.005_bb0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1369-1600.2011.00427.x","article-title":"Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers","volume":"18","author":"Bedi","year":"2013","journal-title":"Addiction Biology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Current Drug Safety"},{"issue":"4\u20135","key":"10.1016\/bs.irn.2016.02.005_bb0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.physbeh.2007.11.007","article-title":"Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties","volume":"93","author":"Bergman","year":"2008","journal-title":"Physiology & Behavior"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","article-title":"The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research","volume":"229","author":"Bossert","year":"2013","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0070","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1360-0443.1999.94913114.x","article-title":"Marijuana withdrawal among adults seeking treatment for marijuana dependence","volume":"94","author":"Budney","year":"1999","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1151\/ASCP07414","article-title":"Marijuana dependence and its treatment","volume":"4","author":"Budney","year":"2007","journal-title":"Addiction Science & Clinical Practice"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","article-title":"Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms","volume":"86","author":"Budney","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550490802408936","article-title":"A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence","volume":"18","author":"Carpenter","year":"2009","journal-title":"American Journal on Addictions"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s002130000481","article-title":"Cannabinoid receptors and reward in the rat: A conditioned place preference study","volume":"151","author":"Cheer","year":"2000","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1369-1600.2012.00461.x","article-title":"A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers","volume":"18","author":"Cooper","year":"2013","journal-title":"Addiction Biology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-010-1875-y","article-title":"Opioid antagonism enhances marijuana's effects in heavy marijuana smokers","volume":"211","author":"Cooper","year":"2010","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0740-5472(01)00179-9","article-title":"A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder","volume":"21","author":"Copeland","year":"2001","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"24","key":"10.1016\/bs.irn.2016.02.005_bb0115","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.1523\/JNEUROSCI.21-24-09867.2001","article-title":"Prevention of cannabinoid withdrawal syndrome by lithium: Involvement of oxytocinergic neuronal activation","volume":"21","author":"Cui","year":"2001","journal-title":"Journal of Neuroscience"},{"issue":"8","key":"10.1016\/bs.irn.2016.02.005_bb0120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tips.2005.06.002","article-title":"Cannabinoid CB1 receptors control conditioned drug seeking","volume":"26","author":"De Vries","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"issue":"11","key":"10.1016\/bs.irn.2016.02.005_bb0125","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1360-0443.2003.00437.x","article-title":"Exploring the association between cannabis use and depression","volume":"98","author":"Degenhardt","year":"2003","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsat.2003.09.005","article-title":"The Cannabis youth treatment (CYT) study: Main findings from two randomized trials","volume":"27","author":"Dennis","year":"2004","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0135","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0269881115615104","article-title":"The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial","volume":"30","author":"Englund","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: Mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s002130100734","article-title":"Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats","volume":"156","author":"Fattore","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2016.02.005_bb0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1615\/CritRevNeurobiol.v16.i12.160","article-title":"Cannabinoids and reward: Interactions with the opioid system","volume":"16","author":"Fattore","year":"2004","journal-title":"Critical Reviews in Neurobiology"},{"issue":"5","key":"10.1016\/bs.irn.2016.02.005_bb0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/resp.12298","article-title":"Cannabis smoking and respiratory health: Consideration of the literature","volume":"19","author":"Gates","year":"2014","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0165","doi-asserted-by":"crossref","first-page":"754.e1","DOI":"10.1016\/j.ahj.2005.11.006","article-title":"The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers","volume":"151","author":"Gorelick","year":"2006","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1016\/bs.irn.2016.02.005_bb0170","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1521-0391.2009.00027.x","article-title":"N-acetylcysteine (NAC) in young marijuana users: An open-label pilot study","volume":"19","author":"Gray","year":"2010","journal-title":"American Journal on Addictions"},{"issue":"5","key":"10.1016\/bs.irn.2016.02.005_bb0180","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/156800705774322111","article-title":"Cannabinoids","volume":"4","author":"Grotenhermen","year":"2005","journal-title":"Current Drug Targets. CNS and Neurological Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/add.12703","article-title":"What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?","volume":"110","author":"Hall","year":"2015","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0190","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.npp.1301243","article-title":"Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers","volume":"32","author":"Haney","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-002-1279-8","article-title":"Interaction between naltrexone and oral THC in heavy marijuana smokers","volume":"166","author":"Haney","year":"2003","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/bs.irn.2016.02.005_bb0200","first-page":"101","article-title":"Factors influencing marijuana self-administration by humans","volume":"8","author":"Haney","year":"1997","journal-title":"Behavioural Pharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2016.02.005_bb0205","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/npp.2013.54","article-title":"Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-010-1888-6","article-title":"Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse","volume":"211","author":"Haney","year":"2010","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0220","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","article-title":"Marijuana withdrawal in humans: Effects of oral THC or divalproex","volume":"29","author":"Haney","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked Cannabis","author":"Haney","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2016.02.005_bb0230","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2015.108","article-title":"Naltrexone maintenance decreases Cannabis self-administration and subjective effects in daily Cannabis smokers","volume":"40","author":"Haney","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002130050848","article-title":"Abstinence symptoms following oral THC administration to humans","volume":"141","author":"Haney","year":"1999","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0240","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002130050849","article-title":"Abstinence symptoms following smoked marijuana in humans","volume":"141","author":"Haney","year":"1999","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0376-8716(02)00084-4","article-title":"Effects of oral THC maintenance on smoked marijuana self-administration","volume":"67","author":"Hart","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0250","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-002-1231-y","article-title":"Comparison of smoked marijuana and oral delta(9)-tetrahydrocannabinol in humans","volume":"164","author":"Hart","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0255","series-title":"Addiction: A disorder of choice","author":"Heyman","year":"2009"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0260","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0265","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0270","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"Huggins","year":"2012","journal-title":"Pain"},{"issue":"10","key":"10.1016\/bs.irn.2016.02.005_bb0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728210902736568","article-title":"Cannabinoid receptor antagonists: Pharmacological opportunities, clinical experience, and translational prognosis","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"24","key":"10.1016\/bs.irn.2016.02.005_bb0285","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00213-014-3611-5","article-title":"Lithium carbonate in the management of cannabis withdrawal: A randomized placebo-controlled trial in an inpatient setting","volume":"231","author":"Johnston","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0290","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1749-6632.1976.tb49901.x","article-title":"Clinical studies of cannabis tolerance and dependence","volume":"282","author":"Jones","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8\u20139 Suppl.","key":"10.1016\/bs.irn.2016.02.005_bb0295","doi-asserted-by":"crossref","first-page":"143S","DOI":"10.1002\/j.1552-4604.1981.tb02589.x","article-title":"Clinical relevance of cannabis tolerance and dependence","volume":"21","author":"Jones","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0300","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1369-1600.2010.00258.x","article-title":"Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist","volume":"16","author":"Justinova","year":"2011","journal-title":"Addiction Biology"},{"issue":"11","key":"10.1016\/bs.irn.2016.02.005_bb0305","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nn.3540","article-title":"Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid","volume":"16","author":"Justinova","year":"2013","journal-title":"Nature Neuroscience"},{"issue":"12","key":"10.1016\/bs.irn.2016.02.005_bb0310","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1038\/npp.2008.21","article-title":"Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant","volume":"33","author":"Justinova","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0315","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/npp.2015.62","article-title":"Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse","volume":"40","author":"Justinova","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"19","key":"10.1016\/bs.irn.2016.02.005_bb0320","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1523\/JNEUROSCI.5073-13.2014","article-title":"Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on delta9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys","volume":"34","author":"Justinova","year":"2014","journal-title":"Journal of Neuroscience"},{"issue":"23","key":"10.1016\/bs.irn.2016.02.005_bb0325","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1523\/JNEUROSCI.0951-05.2005","article-title":"The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys","volume":"25","author":"Justinova","year":"2005","journal-title":"Journal of Neuroscience"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2016.02.005_bb0330","first-page":"186","article-title":"The opioid antagonist naltrexone reduces the reinforcing effects of delta 9 tetrahydrocannabinol (THC) in squirrel monkeys","volume":"173","author":"Justinova","year":"2004","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0335","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00213-003-1484-0","article-title":"Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys","volume":"169","author":"Justinova","year":"2003","journal-title":"Psychopharmacology"},{"issue":"19","key":"10.1016\/bs.irn.2016.02.005_bb0340","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1523\/JNEUROSCI.6058-10.2011","article-title":"The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys","volume":"31","author":"Justinova","year":"2011","journal-title":"Journal of Neuroscience"},{"issue":"25","key":"10.1016\/bs.irn.2016.02.005_bb0345","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.2174\/13816128113199990620","article-title":"Acute and long-term effects of cannabis use: A review","volume":"20","author":"Karila","year":"2014","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2010.07.010","article-title":"Allosteric modulation of G protein-coupled receptors: A pharmacological perspective","volume":"60","author":"Keov","year":"2011","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0355","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","article-title":"Cannabidiol potentiates delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats","volume":"218","author":"Klein","year":"2011","journal-title":"Psychopharmacology"},{"issue":"23","key":"10.1016\/bs.irn.2016.02.005_bb0360","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.2174\/1381612821666150619093940","article-title":"Is there a place for off-label pharmacotherapy in Cannabis use disorder? A review on efficacy and safety","volume":"21","author":"Laprevote","year":"2015","journal-title":"Current Pharmaceutical Design"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0365","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","article-title":"Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence","volume":"312","author":"Le Foll","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0375","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1521-0391.2014.12088.x","article-title":"Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment","volume":"23","author":"Lee","year":"2014","journal-title":"American Journal on Addictions"},{"key":"10.1016\/bs.irn.2016.02.005_bb0380","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pbb.2014.01.002","article-title":"Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model","volume":"118","author":"Lefever","year":"2014","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2016.02.005_bb0385","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2016.02.005_bb0390","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0395","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10550490490265280","article-title":"Pharmacotherapy for marijuana dependence: A double-blind, placebo-controlled pilot study of divalproex sodium","volume":"13","author":"Levin","year":"2004","journal-title":"American Journal on Addictions"},{"key":"10.1016\/bs.irn.2016.02.005_bb0400","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Translational Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2016.02.005_bb0405","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","article-title":"Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects","volume":"73","author":"Li","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2016.02.005_bb0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0091-3057(01)00514-7","article-title":"Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine","volume":"69","author":"Lichtman","year":"2001","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/187152710790966623","article-title":"Blockade of the cannabinoid CB1 receptor and alcohol dependence: Preclinical evidence and preliminary clinical data","volume":"9","author":"Maccioni","year":"2010","journal-title":"CNS & Neurological Disorders Drug Targets"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2016.02.005_bb0420","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","article-title":"Effects of cannabidiol on the function of alpha7-nicotinic acetylcholine receptors","volume":"720","author":"Mahgoub","year":"2013","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0425","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1037\/0022-006X.72.3.455","article-title":"Brief treatments for cannabis dependence: Findings from a randomized multisite trial","volume":"72","author":"Marijuana Treatment Project Research Group","year":"2004","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0430","first-page":"Cd008940","article-title":"Pharmacotherapies for cannabis dependence","volume":"12","author":"Marshall","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0435","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0306-4522(98)00052-9","article-title":"Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice","volume":"85","author":"Martellotta","year":"1998","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2016.02.005_bb0440","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0445","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2014.08.011","article-title":"Achieving cannabis cessation\u2014Evaluating N-acetylcysteine treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network","volume":"39","author":"McClure","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0450","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"British Journal of Pharmacology"},{"issue":"11 Suppl.","key":"10.1016\/bs.irn.2016.02.005_bb0455","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: An overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0460","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/sj.npp.1300957","article-title":"Involvement of kappa\/dynorphin system in WIN 55,212-2 self-administration in mice","volume":"31","author":"Mendizabal","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2016.02.005_bb0465","doi-asserted-by":"crossref","first-page":"a012229","DOI":"10.1101\/cshperspect.a012229","article-title":"A brain on cannabinoids: The role of dopamine release in reward seeking","volume":"2","author":"Oleson","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"12","key":"10.1016\/bs.irn.2016.02.005_bb0470","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1360-0443.2007.02011.x","article-title":"Self-administration of drugs in animals and humans as a model and an investigative tool","volume":"102","author":"Panlilio","year":"2007","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0475","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.118","article-title":"Cannabinoid abuse and addiction: Clinical and preclinical findings","volume":"97","author":"Panlilio","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0480","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1476-5381.2010.00775.x","article-title":"Animal models of cannabinoid reward","volume":"160","author":"Panlilio","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0485","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"5\u20136","key":"10.1016\/bs.irn.2016.02.005_bb0490","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lfs.2009.05.015","article-title":"Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure","volume":"85","author":"Polissidis","year":"2009","journal-title":"Life Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0495","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1037\/a0033661","article-title":"Marijuana's dose-dependent effects in daily marijuana smokers","volume":"21","author":"Ramesh","year":"2013","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2016.02.005_bb0500","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S1461145711001830","article-title":"Naltrexone does not attenuate the effects of intravenous delta9-tetrahydrocannabinol in healthy humans","volume":"15","author":"Ranganathan","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0505","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00213-002-1302-0","article-title":"Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats","volume":"166","author":"Robinson","year":"2003","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0510","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1471-4159.2009.05898.x","article-title":"Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine","volume":"108","author":"Rodriguez-Gaztelumendi","year":"2009","journal-title":"Journal of Neurochemistry"},{"issue":"11","key":"10.1016\/bs.irn.2016.02.005_bb0515","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.tips.2007.10.006","article-title":"Allosterism and cannabinoid CB(1) receptors: The shape of things to come","volume":"28","author":"Ross","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"7","key":"10.1016\/bs.irn.2016.02.005_bb0520","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2016.02.005_bb0525","first-page":"180","article-title":"The use of second-order schedules to study the influence of environmental stimuli on drug-seeking behavior","volume":"84","author":"Schindler","year":"1988","journal-title":"NIDA Research Monograph"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2016.02.005_bb0530","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2010.02.005","article-title":"Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys","volume":"633","author":"Schindler","year":"2010","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2016.02.005_bb0535","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nprot.2006.167","article-title":"Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats","volume":"1","author":"Solinas","year":"2006","journal-title":"Nature Protocols"},{"issue":"21","key":"10.1016\/bs.irn.2016.02.005_bb0540","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1523\/JNEUROSCI.0027-07.2007","article-title":"Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse","volume":"27","author":"Solinas","year":"2007","journal-title":"Journal of Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2016.02.005_bb0545","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1037\/0022-006X.68.5.898","article-title":"Comparison of extended versus brief treatments for marijuana use","volume":"68","author":"Stephens","year":"2000","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0550","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/jpet.110.168435","article-title":"Rimonabant-induced delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: Discriminative stimulus effects and other withdrawal signs","volume":"334","author":"Stewart","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2b","key":"10.1016\/bs.irn.2016.02.005_bb0555","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1476-5381.2011.01388.x","article-title":"The fatty acid amide hydrolase inhibitor URB 597: Interactions with anandamide in rhesus monkeys","volume":"164","author":"Stewart","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"15","key":"10.1016\/bs.irn.2016.02.005_bb0560","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00213-015-3907-0","article-title":"Cannabinoid withdrawal in mice: Inverse agonist vs neutral antagonist","volume":"232","author":"Tai","year":"2015","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2016.02.005_bb0565","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/80577","article-title":"Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys","volume":"3","author":"Tanda","year":"2000","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2016.02.005_bb0570","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1016\/j.drugalcdep.2015.07.604","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"156","author":"Trigo","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/bs.irn.2016.02.005_bb0575","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu094","article-title":"Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers","volume":"18","author":"Tudge","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6166","key":"10.1016\/bs.irn.2016.02.005_bb0580","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.1243985","article-title":"Pregnenolone can protect the brain from cannabis intoxication","volume":"343","author":"Vallee","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.irn.2016.02.005_bb0585","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.drugalcdep.2004.11.001","article-title":"Cannabis withdrawal in adolescent treatment seekers","volume":"78","author":"Vandrey","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2016.02.005_bb0590","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","article-title":"The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users","volume":"128","author":"Vandrey","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0595","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/FBP.0b013e3282186cf2","article-title":"Lack of evidence for appetitive effects of delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents","volume":"18","author":"Vlachou","year":"2007","journal-title":"Behavioural Pharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2016.02.005_bb0600","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00008877-199708000-00001","article-title":"The effects of a monetary alternative on marijuana self-administration","volume":"8","author":"Ward","year":"1997","journal-title":"Behavioural Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0605","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00952990.2013.819362","article-title":"Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: A double-blind placebo-controlled study","volume":"40","author":"Weinstein","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/bs.irn.2016.02.005_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)12022-3","article-title":"Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys","volume":"275","author":"Wiley","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2016.02.005_bb0615","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0091-3057(01)00694-3","article-title":"Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine","volume":"71","author":"Williams","year":"2002","journal-title":"Pharmacology, Biochemistry and Behavior"}],"container-title":["International Review of Neurobiology","Animal Models for Medications Screening to Treat Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774216300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774216300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:39:57Z","timestamp":1748803197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774216300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9780128040133"],"references-count":123,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2016.02.005","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}